Concepedia

Discontinuation of Primary and Secondary<i>Toxoplasma gondii</i>Prophylaxis Is Safe in HIV‐Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial

José M. Miró, Juan Carlos López, Daniel Podzamczer, José M. Peña, J. Alberdi, Estebán Martínez, Peré Domingo, Jaime Cosín, Xavier Claramonte, José Ramón Arribas,

Clinical Infectious Diseases · 2006 · 52 citations · 37 references

DOI Full text

Open access

Abstract

In HIV-infected adult patients receiving effective highly active antiretroviral therapy, primary and secondary prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count has increased to > or =200 cells/mm3 for >3 months.

References

37

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

Frank J. Palella, Kathleen M. Delaney, Anne C. Moorman et al. · New England Journal of Medicine · 1998 · 9.5K citations

Prevention and Control of Influenza; Recommendations of the Advisory Committee on Immunization Practices (ACIP)

PsycEXTRA Dataset · 2002 · 1.7K citations

Virus Epidemiology, Strain Selection, Advisory Committee +21

Changing patterns of mortality across Europe in patients infected with HIV-1

Amanda Mocroft, Stefano Vella, Antonio Chiesi et al. · The Lancet · 1998 · 1.3K citations

Sexual Health, Epidemiological Trend, Epidemiological Outcome +7

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

Li Ts, Roland Tubiana, Christine Katlama et al. · The Lancet · 1998 · 554 citations

Cd4 T-cell Function, Human Retrovirus, T-regulatory Cell +11

Bruno Ledergerber, Matthias Egger, Véronique Erard et al. · PubMed · 1999 · 480 citations